A
Astria Therapeutics
Catabasis Pharmaceuticals discovers and develops innovative drugs for treating inflammatory conditions
About Astria Therapeutics
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for allergic and immunological diseases.
The company's lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe and recurrent episodes of swelling.
Astria is also developing other preclinical programs for the treatment of allergic and immunologic diseases. The company's business model is based on developing and commercializing its product candidates, either on its own or in collaboration with other pharmaceutical companies. Astria's target market is the global market for HAE and other allergic and immunologic diseases, which is estimated to be worth billions of dollars.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- Boston, United States
- Listing
- IPO 2015
- Employees
- 120
- Open positions
- None listed
- Dealroom signal
- 61.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Inflammatory Diseases, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Feb 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2025 | $700M | $700M | BioCryst Pharmaceuticals | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2024 | $125M | — | Adage Capital · Perceptive Advisors · Driehaus Capital Management · RA Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Astria Therapeutics is 3.6K monthly website visits, up 2.9% over the last three months. Astria Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
MedImmune Ventures- AVAdvanced Technology Ventures
Clarus Ventures
SV Health Investors
Series B and later6 investors entered at this stage
Adage Capital
Perceptive Advisors
Driehaus Capital Management
RA Capital Management
TCGX- VPVenrock Healthcare Capital Partners
Other known investors2 additional known investors
BioCryst Pharmaceuticals
Xontogeny
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Astria Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Astria Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.